Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA4 | P22748 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18393568 | 0.82 | CYP19A1 (0.30) | BACE1 | |
| SCHEMBL2463236 | 0.77 | MAPT (0.32) | HPGDALDH1A1BACE1MAPT | |
| SCHEMBL18784708 | 0.75 | BACE1 (0.30) | HPGDBACE1MAPT | |
| SCHEMBL28556535 | 0.73 | BACE1 (0.31) | HPGDBACE1MAPT | |
| SCHEMBL5773325 | 0.72 | HTR2A (0.39) | — | |
| SCHEMBL18393601 | 0.72 | CA2 (0.37) | CA2CA4CA1CA6IMPDH2 | |
| SCHEMBL192582 | 0.72 | AGXT (0.47) | — | |
| SCHEMBL8256403 | 0.72 | HTR2A (0.36) | HPGDALDH1A1MEN1KMT2A | |
| SCHEMBL3151669 | 0.72 | F2RL3 (0.30) | — | |
| SCHEMBL5777589 | 0.72 | IDO1 (0.41) | HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10954219-B2 | 1,3-benzodioxole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-03-23 | — | — | US | disclosed |
| US-20180282313-A1 | 1,3-BENZODIOXOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-10-04 | — | — | US | disclosed |
| US-10017500-B2 | 1,3-benzodioxole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-07-10 | — | — | US | disclosed |
| US-10017500-B2 | 1,3-benzodioxole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-07-10 | — | — | US | disclosed |
| US-20170073335-A1 | 1,3-BENZODIOXOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-03-16 | — | — | US | disclosed |
| US-20170073335-A1 | 1,3-BENZODIOXOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-03-16 | — | — | US | disclosed |
| US-20170073335-A1 | 1,3-BENZODIOXOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-03-16 | — | — | US | disclosed |
| EP-3121175-A1 | 1,3-BENZODIOXOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180282313-A1 | 1,3-BENZODIOXOLE DERIVATIVE | EZH1, EZH2, BMI1 | CA2 1669/4885CA4 2461/4885CA1 3237/4885 |
| US-20170073335-A1 | 1,3-BENZODIOXOLE DERIVATIVE | EZH1, EZH2, BMI1 | CA2 1669/4885CA4 2461/4885CA1 3237/4885 |
| US-10017500-B2 | 1,3-benzodioxole derivative | EZH1, EZH2, BMI1 | CA2 1669/4885CA4 2461/4885CA1 3237/4885 |
| US-10954219-B2 | 1,3-benzodioxole derivative | EZH1, EZH2, BMI1 | CA2 1669/4885CA4 2461/4885CA1 3237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.